Next-Generation Sequencing Services Market Size, Share, and Trends 2025 to 2035

Next-generation Sequencing Services Market Size and Growth 2025 to 2035

The global next-generation sequencing services market size is calculated at USD 8.15 billion in 2025, grew to USD 9.99 billion in 2026, and is projected to reach around USD 62.32 billion by 2035. The market is expanding at a CAGR of 22.56% between 2025 and 2035.

Key Takeaways 

• By region, North America held the largest market share in 2024. 
• By region, Asia-pacific is seen to have the fastest growth rate throughout the forecast period.
• By service type, the human genome segment dominated the market in 2024.
• By service type, the gene regulation services segment is projected to grow at the fastest rate all throughout the forecast period.
• By workflow, the sequencing segment led the market as of this year.
• By workflow, the data analysis service segment is projected to grow at the fastest rate over the forecast period.
• By end user, the academic research centers segment dominated the market in 2024.
• By end user, hospitals and clinics are expected to witness the fastest rate of growth in the upcoming years.

U.S. Next-generation Sequencing Services Market Size and Growth 2025 to 2035

The U.S. next-generation sequencing services market size is calculated at USD 2.87 billion in 2025 and is expected to reach nearly USD 21.97 billion in 2034, accelerating at a strong CAGR of 20.33% between 2025 and 2035.

How Did North America Dominate the Next-generation Sequencing Services Market?

North America dominated the market in 2024. This dominance is due to the region’s broad use of next-generation sequencing technologies. The region benefits from a strong government support for genomics research, a well-established healthcare system, and has also witnessed a rising incidence of chronic illnesses. It also is home to some of the of major market players, who have easy access to cutting-edge genomic research technology. Through all these factors, we can see how North America has strategically placed itself as a global leader and competitor. 

Asia Pacific Next-generation Sequencing Services Market Trends

Asia Pacific is expected to grow at the fastest rate during the forecast period. This growth is because next-generation sequencing is becoming more and more advanced and cheaper, the number of cancer cases are rising, and awareness about these new technologies becomes widespread. This technology is being increasingly adopted by emerging economies like China, Japan and India, and since it is less expensive, countries are quick to adopt it, thus fostering innovation and growth.

What is Next-generation Sequencing Services?

Next-generation sequencing servics is an instrument that is used for a variety of applications, including medical diagnostics, personalized treatment and scientific research. The next generation sequencing services market deals with products, services and devices that are needed for sequencing of genetic materials. The market also consists of research and development associated with next generation sequencing (NGS). This technique is used to identify the DNA or RNA sequence in order to investigate genetic variations that are linked to illnesses or other biological phenomena.

What are the Key Trends in the Market?

• The utilization of next-generation sequencing (NGS) in clinical applications is rapidly increasing, all the way from diagnoses to personalized treatment strategies.
• Enhanced sequencing platforms have helped to increase throughput, enabling the capture of larger volumes of sequencing data at less time and at a lower cost.
• NGS data is further optimized with the help of bioinformatics tools and data analysis solutions. The large volumes of genomic data produced by NGS technology are processed, analyzed, and understood with the help of advanced computational resources.
• Single-cell sequencing is a significant trend in the market, providing new insights into cellular heterogeneity and functional genomics at the single-cell level. This enables detailed investigations into gene expression, DNA mutations, epigenetic changes, and spatial transcriptomics, among other genomic characteristics.

Role of AI in Next Generation Sequencing Services Market

AI and machine learning are greatly revolutionizing the NGS services market by improving variant calling accuracy and streamlining workflows. Big data algorithms and artificial intelligence are being increasingly integrated into workflows as they offer efficient strategy development tools and algorithms that help to deduce meaning from complex and immense data produced via NGS. This is done by identifying patterns and co-relations that help in unraveling and analyzing relevant clinical information by deciphering genomic data. 

• Apart from traditional machine learning methods, deep learning approach is also gaining traction in today’s market, which uses multiple neural networks in supervised, unsupervised as well as semi-supervised methods.

Deep neural network architecture methods are also being actively implemented in domains like variant identification, metagenomics, transcriptomics and epigenomics. NGS-generated data can be used for various processes and activities such as classification, prognostication, disease surveillance and diagnosis. It even helps in the identification of patients that are suitable for targeted treatment by implementing big data management and advanced machine leaning methods. Through all these factors, we can see how Artificial Intelligence and Machine Learning tools and systems are fostering innovation and propelling the market forward.

Report Scope of Next-generation Sequencing Services Market

Market Dynamics 

Driver

Rise of Precision Medicine

A key driver that is propelling the next-generation sequencing services market forward is the increasing adoption of precision medicine and genomic testing for early disease detection, treatment selection and even personalized therapy. The increasing global burden of cancer and complex genetic disorders continues to drive a high demand for advanced diagnostics processes and treatment plans.

NGS platforms are now helping clinicians to analyze multiple genes simultaneously, identify actionable mutations, and then decide on patient-specific treatment plans. The rising integration of NGS in non-invasive prenatal testing (NIPT), rare disease diagnosis, and infectious disease surveillance further supports this market’s growth.

Pharmaceutical and biotechnology companies all over the world are also seen adopting advanced NGS in drug discovery and clinical trials, by using genomic insights, stratifying patient groups, and accelerating vaccine and therapeutic development.

Restraint

Data and Cost Complexities

Despite multiple growth prospects, the market does have its fair share of challenges that could potentially hinder its growth and development. One such restraint in the market is the immense complexity and volume of data generated, which can be quite challenging for analysis and management. A single human genome sequence can produce over hundreds of gigabytes of raw data, analyzing this information requires sophisticated bioinformatics tools and highly skilled professionals. This sheer scale of the data necessitates robust and costly IT infrastructure for storage and processing. All these factors can create complexities in the workflow and also incur heavy financial expenses, thus slowing down market growth.

Opportunity

Technological and Medical Advancements

The next-generation sequencing services market is witnessing new areas of opportunities, driven by technology innovation, clinical adoption and large-scale genomics initiatives. One of the most significant opportunities in the market is the expansion of clinical genomics and precision medicine. We are able to see that NGS is becoming integral to oncology, rare disease diagnosis and infectious disease surveillance.

Another similar opportunity is the rise of long-read sequencing technologies such as nanopore and single-molecule real-time (SMRT) sequencing, which provides superior accuracy in identifying structural variants, repetitive regions and epigenetic modifications.

These advancements are bringing in new, cutting-edge technologies to the market faster as well as broadening NGS applications in both, research and healthcare. The integration of AI and machine learning tools in bioinformatics is also helping in transforming variant detection and interpretation. AI-driven analytics platforms are now seen helping laboratories reduce turnaround times and improve diagnostic accuracy, while cloud-based data solutions are democratizing access to genomic analysis for small scale institutions.

Segmental Analysis

By Service Type Insights

The human genome segment dominated the market in 2024. Human genome sequencing services offers access to genomic information related to human genes, thus providing solutions for personalized medicine, biomarker discovery, cancer-associated gene information and pharmacogenomics.

The gene regulation services segment is projected to grow at the fastest rate throughout the forecast period, due to the growing demand for new genomic tools in order to analyze transcriptional and epigenetic mechanisms. Additionally, the increasing adoption of advanced NGS techniques, CRISPR-based genomics, and single-cell sequencing also contributes to this segment’s growth.

By Workflow Insights

The sequencing segment led the market as of this year. This dominance can be attributed to the fact that companies increasingly adopting various scientific endeavors to boost the adoption of sequencing services. This segment offers a range of NGS services for a diverse plethora of sample types. The company generates publication-ready data to support the success of customer research programs across multiple domains, including other domains such as agriculture, biomedical and environmental science.

The data analysis service segment is projected to grow at the fastest rate over the forecast period. This growth is driven by the increasing adoption of cloud-based analytics, AI-enabled pipelines and integrated multi-omics platforms, as well as the growing demand for personalized medicine and precision medicine-related research.

By End Use Insights

The research centers and universities segment held the largest market share as of 2024. The dominance of this segment is due to a rise in Research and development funding, high demand for NGS services, and an increasing number of comparative and evolutionary genomic studies in universities. This research helps us better grasp the role that genes play in the development of certain diseases. Additionally, there is a rise in the number of researches undertaken by universities which is expected to bring various growth opportunities for NGS service providers in the upcoming years.

The hospitals and clinics segment is seen to be the fastest growing, throughout the forecasted period. This growth is driven by the increasing integration of next-generation sequencing (NGS) technologies into regular clinical workflows. The growing demand for precision diagnostics, particularly in the field of oncology, the detection of rare diseases, and the management of infectious diseases, is encouraging hospitals and clinics to adopt NGS-based testing solutions.

Top Key Players 

• Illumina
• BGI
• Eurofins GATC Biotech GmbH
• Perkin Elmer, Inc.
• DNASTAR, Inc.
• Genomatix GmbH
• PierianDx
• Oxford Nanopore Technologies
• Bio-Rad Laboratories, Inc.
• QIAGEN
• F. Hoffman-La Roche Ltd.
• Thermo Fisher Scientific, Inc.

Recent Developments

• In February 2025, Roche unveiled a new class of next-generation sequencing with its novel sequencing by expansion technology. The SBX technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditions. Combined with an innovative, high throughput sensor module, SBX uses expanded synthetic molecules to determine the DNA sequence of a target molecule, creating an ultra-rapid, scalable and flexible technology.
• In July 2025, Thermo Fisher Scientific enabled precision oncology advancements in the U.S. by launching the Oncomine Comprehensive Assay Plus on the Genexus System, accelerating next-day comprehensive genomic profiling for researchers. The Genexus Dx Integrated Sequencer delivers an effortless user experience while enabling regulatory compliance for clinical labs. With a single touchpoint and only 10 minutes of hands-on time, the Genexus Dx Integrated Sequencer completes nucleic acid-to-report workflows in a single day.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the next-generation sequencing services market.

By Service Type

• Human Genome Sequencing Services
• Single Cell Sequencing Services
• Microbial Genome-based Sequencing Services
• Gene Regulation Services
• Animal & Plant Sequencing Services
• Other Sequencing Services

By Workflow

• Pre-sequencing
• Sequencing
• Data Analysis

By End User

• Research Centers and Universities
• Hospitals and Clinics
• Pharma and Biotech Entities
• Others

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)